Sugi Predict

Sugi Predict / Compounds / SCHEMBL377111

SCHEMBL377111

SCHEMBL377111

O=[N+]([O-])c1cc(S(=O)(=O)Cl)ccc1F

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ VCAM1 P19320 7/20 0.73
▸ ALDH1A1 P00352 3/20 0.56
▸ MAPT P10636 3/20 0.56
▸ GAA P10253 2/20 0.56
▸ NPSR1 Q6W5P4 2/20 0.56
▸ LMNA P02545 2/20 0.56
▸ HTT P42858 2/20 0.56
▸ MITF O75030 1/20 0.56
▸ HIF1A Q16665 1/20 0.56
▸ ATM Q13315 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ CA1 P00915 4/20 0.43
▸ CA12 O43570 3/20 0.43
▸ CA2 P00918 3/20 0.43
▸ CA9 Q16790 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ MMP2 P08253 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17106 0.85 ATM (0.58) VCAM1ALDH1A1MAPTGAANPSR1
SCHEMBL29510874 0.85 VCAM1 (1.00) VCAM1ALDH1A1MAPTGAANPSR1
SCHEMBL133996 0.85 VCAM1 (1.00) VCAM1ALDH1A1MAPTGAANPSR1
SCHEMBL6417727 0.85 VCAM1 (1.00) VCAM1ALDH1A1MAPTGAANPSR1
SCHEMBL3813276 0.82 VCAM1 (0.50) VCAM1ALDH1A1HTTCA1CA12
SCHEMBL8195359 0.81 VCAM1 (0.73) VCAM1ALDH1A1MAPTGAANPSR1
SCHEMBL1491246 0.81 VCAM1 (0.73) VCAM1ALDH1A1MAPTGAANPSR1
Potassium Ion SCHEMBL11769055 0.81 VCAM1 (0.73) VCAM1ALDH1A1MAPTGAANPSR1
SCHEMBL550564 0.81 VCAM1 (0.73) VCAM1ALDH1A1MAPTGAANPSR1
SCHEMBL29077442 0.81 VCAM1 (0.73) VCAM1ALDH1A1MAPTGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115872963-A Synthetic method of Venetork intermediate 南京哈柏医药科技有限公司 2023-03-31 — — CN claimed
CN-112661677-A Synthesis method of antiviral drug intermediate 4-amino-3-nitrobenzenesulfonamide 南京哈柏医药科技有限公司 2021-04-16 — — CN claimed
CN-1266125-C Method for preparing 2-chlorine-4-fluorin-nitrobenzene sulfonyl chloride ZHEJIANG POLYTECHNIC UNIVERSIT (CN) 2006-07-26 — — CN claimed
CN-1660797-A Method for preparing 2-chlorine-4-fluorin-nitrobenzene sulfonyl chloride UNIV ZHEJIANG POLYTECHNIC (CN) 2005-08-31 — — CN claimed
WO-2026106403-A1 NOVEL NRF2 ACTIVATOR AND USE THEREOF 나손사이언스(주) 2026-05-21 — — WO disclosed
US-12583853-B2 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases NEWAVE PHARMACEUTICAL INC. (US) 2026-03-24 — — US disclosed
US-12552784-B2 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases NEWAVE PHARMACEUTICAL INC. (US) 2026-02-17 — — US disclosed
EP-4634155-A1 RBM39 SULFONAMIDE INHIBITORS Recursion Pharmaceuticals, Inc. (US) 2025-10-22 — — EP disclosed
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 — — US disclosed
US-20250051329-A1 BCL-2 INHIBITORS NEWAVE PHARMACEUTICAL INC (US) 2025-02-13 — — US disclosed
US-12220419-B2 BCL-2 inhibitors NEWAVE PHARMACEUTICAL INC. (US) 2025-02-11 — — US disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 — — US disclosed
US-6284923-B1 BENZENESULFONIMIDES FOR TREATMENT OF CANCER AND ANTICHOLESTEROL AGENTS TULARIK INC 2001-09-04 — — US disclosed
WO-2000035865-A2 TUBULIN-BINDING AGENTS TULARIK INC. (US) 2000-06-22 — — WO disclosed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 — — EP disclosed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 — — WO disclosed
US-4444867-A DYE DIFFUSION TRANSFER AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) 1984-04-24 — — US disclosed
US-4008208-A Compositions having inhibited ability to promote platelet aggregation or fibrin clot formation THE UPJOHN COMPANY (US) 1977-02-15 — — US disclosed
US-3975371-A Aromatic azo sulfonylnitrene compounds THE UPJOHN COMPANY (US) 1976-08-17 — — US disclosed
US-3954583-A Photochemical process THE UPJOHN COMPANY (US) 1976-05-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12220419-B2 BCL-2 inhibitors BCL2L10, BCL2, BCL2L11 VCAM1 1159/4885ALDH1A1 3743/4885MAPT 4392/4885
US-20250051329-A1 BCL-2 INHIBITORS BCL2L1, BCL2, BCL2A1 VCAM1 587/4885ALDH1A1 2239/4885MAPT 4295/4885
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 VCAM1 3125/4885ALDH1A1 1411/4885MAPT 3262/4885
US-12583853-B2 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases BCL3, BCL9, BCL6 VCAM1 2376/4885ALDH1A1 3564/4885MAPT 3633/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 VCAM1 3092/4885ALDH1A1 1483/4885MAPT 3085/4885
US-12552784-B2 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases BCL3, BCL2A1, BCL6 VCAM1 1933/4885ALDH1A1 3652/4885MAPT 3989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.